1. NF-κB
    Apoptosis
  2. NF-κB
    Apoptosis
  3. DCZ0415

DCZ0415 

Cat. No.: HY-130603 Purity: 99.96%
Handling Instructions

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients.

For research use only. We do not sell to patients.

DCZ0415 Chemical Structure

DCZ0415 Chemical Structure

CAS No. : 2242470-43-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
10 mM * 1  mL in DMSO USD 160 In-stock
Estimated Time of Arrival: December 31
5 mg USD 145 In-stock
Estimated Time of Arrival: December 31
10 mg USD 250 In-stock
Estimated Time of Arrival: December 31
25 mg USD 530 In-stock
Estimated Time of Arrival: December 31
50 mg USD 910 In-stock
Estimated Time of Arrival: December 31
100 mg USD 1575 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].

IC50 & Target[1]

NF-κB

 

In Vitro

DCZ0415 (10, 20 μM; 72 hours) shows a significant decrease in colony formation, indicating it inhibits cell proliferation[1].
DCZ0415 (1.25-40 μM; 72 hours) induces a significant dose-dependent decrease of viability in MM cells[1].
DCZ0415 (10, 20 μM; 24-72 hours) shows a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death[1].
DCZ0415 (10, 20 μM; 24 hours) induces a significant accumulation in G0/G1 MM cells[1].
DCZ0415 (10 μM; 48 hours) decreases the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells[1].
DCZ0415 has IC50s of 1.0–10 μM in CalcuSyn in MM cell lines[1].
DCZ0415 exerts cytotoxic effects by inhibiting DNA 288 synthesis in MM cells[1].

Cell Proliferation Assay[1]

Cell Line: Multiple myeloma (MM) cells
Concentration: 10, 20 μM
Incubation Time: 72 hours
Result: Showed a significant decrease in colony formation, indicating it inhibits cell proliferation.

Cell Viability Assay[1]

Cell Line: MM cells
Concentration: 1.25, 2.5, 5, 10, 20, 40 μM
Incubation Time: 72 hours
Result: Induced a significant dose-dependent decrease of viability.

Apoptosis Analysis[1]

Cell Line: MM cells
Concentration: 10, 20 μM
Incubation Time: 24, 48, 72 hours
Result: Showed a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death.

Cell Cycle Analysis[1]

Cell Line: MM cells
Concentration: 10 and 20 μM
Incubation Time: 24 hours
Result: Induced a significant accumulation in G0/G1 MM cells.

Western Blot Analysis[1]

Cell Line: MM cells
Concentration: 10 μM
Incubation Time: 48 hours
Result: Decreased the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells.
In Vivo

DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice[1].

Animal Model: Nude mice (6-weeks-old) with H929 775 cells[1]
Dosage: 50 mg/kg
Administration: Intraperitoneal injection; every day for 14 days
Result: Significantly reduced the growth of MM cells-induced tumors.
Molecular Weight

356.42

Formula

C₂₃H₂₀N₂O₂

CAS No.

2242470-43-3

SMILES

O=C1N(C2=CC=C(CC3=CC=NC=C3)C=C2)C(C4C5C(C6)C6C(C=C5)C14)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 62.5 mg/mL (175.35 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8057 mL 14.0284 mL 28.0568 mL
5 mM 0.5611 mL 2.8057 mL 5.6114 mL
10 mM 0.2806 mL 1.4028 mL 2.8057 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 6.67 mg/mL (18.71 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution

*All of the co-solvents are provided by MCE.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

DCZ0415DCZ 0415DCZ-0415NF-κBApoptosisNuclear factor-κBNuclear factor-kappaBTRIP13nonhomologousendjoiningrepairanti-myelomadrug-resistantmyelomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DCZ0415
Cat. No.:
HY-130603
Quantity:
MCE Japan Authorized Agent: